SG11201903057XA - Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine - Google Patents

Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine

Info

Publication number
SG11201903057XA
SG11201903057XA SG11201903057XA SG11201903057XA SG11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA SG 11201903057X A SG11201903057X A SG 11201903057XA
Authority
SG
Singapore
Prior art keywords
international
oslo
cholangiocarcinoma
gemcitabine
pct
Prior art date
Application number
SG11201903057XA
Other languages
English (en)
Inventor
Anders Høgset
Per Edvard Walday
Pål Kristian Selbo
Kristin Eivindvik
Lena Finnesand
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1617526.7A external-priority patent/GB201617526D0/en
Priority claimed from GBGB1704719.2A external-priority patent/GB201704719D0/en
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of SG11201903057XA publication Critical patent/SG11201903057XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201903057XA 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine SG11201903057XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1617526.7A GB201617526D0 (en) 2016-10-14 2016-10-14 Method
GBGB1704719.2A GB201704719D0 (en) 2017-03-24 2017-03-24 Method
PCT/EP2017/076257 WO2018069536A1 (en) 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine

Publications (1)

Publication Number Publication Date
SG11201903057XA true SG11201903057XA (en) 2019-05-30

Family

ID=60186250

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903057XA SG11201903057XA (en) 2016-10-14 2017-10-13 Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine

Country Status (13)

Country Link
US (1) US20200338044A1 (ja)
EP (1) EP3525783B1 (ja)
JP (1) JP2019530718A (ja)
KR (1) KR20190068573A (ja)
CN (1) CN110022874A (ja)
AU (1) AU2017342086A1 (ja)
CA (1) CA3040344A1 (ja)
DK (1) DK3525783T3 (ja)
ES (1) ES2841941T3 (ja)
PL (1) PL3525783T3 (ja)
RU (1) RU2019109682A (ja)
SG (1) SG11201903057XA (ja)
WO (1) WO2018069536A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913124D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB201913121D0 (en) * 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
CZ301427B6 (cs) 2000-11-29 2010-02-24 Pci Biotech As Zpusob zavedení molekuly do cytosolu bunky
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
GB0914287D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Compositions

Also Published As

Publication number Publication date
DK3525783T3 (da) 2021-01-18
EP3525783B1 (en) 2020-12-16
US20200338044A1 (en) 2020-10-29
CN110022874A (zh) 2019-07-16
WO2018069536A1 (en) 2018-04-19
EP3525783A1 (en) 2019-08-21
PL3525783T3 (pl) 2021-04-19
CA3040344A1 (en) 2018-04-19
AU2017342086A1 (en) 2019-05-09
RU2019109682A (ru) 2020-11-16
KR20190068573A (ko) 2019-06-18
JP2019530718A (ja) 2019-10-24
ES2841941T3 (es) 2021-07-12
RU2019109682A3 (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
SG11201811432WA (en) Rna for cancer therapy
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201805229YA (en) Means and methods for treating hbv
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201809341PA (en) Mobile robot
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201805001UA (en) Method of treating influenza a